Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Surface Logix |
---|---|
Information provided by: | Surface Logix |
ClinicalTrials.gov Identifier: | NCT00528242 |
To investigate the severity of secondary Raynaud's disease-related attacks during the 14 days 2101 dosing period.
Condition | Intervention | Phase |
---|---|---|
Raynaud's Disease |
Drug: SLx-2101 |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Crossover Assignment, Safety/Efficacy Study |
Official Title: | A Randomized, Double Blind, Placebo-Controlled, Cross-Over Pilot Study to Examine the Safety, Tolerability and Pharmacodynamic Profile of Repeat Oral Doses of SLx-2101 Once Daily for up to 14 Days in Subjects With Secondary Raynaud's Disease. |
Enrollment: | 17 |
Study Start Date: | June 2007 |
Study Completion Date: | March 2008 |
Primary Completion Date: | March 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
SLx-2101 vs. placebo
|
Drug: SLx-2101 |
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | Surface Logix, Inc. ( Warwick Tong, MB, ChB ) |
Study ID Numbers: | SLx-2101-07-04 |
Study First Received: | September 11, 2007 |
Last Updated: | December 17, 2008 |
ClinicalTrials.gov Identifier: | NCT00528242 |
Health Authority: | Germany: Ethics Commission |
Peripheral Vascular Diseases Raynaud Disease Vascular Diseases Neoplasm Metastasis |
Cardiovascular Diseases |